Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

evolocumab × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Gastrointestinal 1 Endocrine 1 CNS 1

Conditions

Multiple Endocrine Neoplasia Type 1 1 Coronary Disease 1

Interventions

Everolimus 55 lutetium Lu 177 dotatate 48 Magnetic Resonance Spectroscopy 32 Cisplatin 25 pembrolizumab 24 Temozolomide 22 gallium Ga 68 dotatate 21 Octreotide 21 lanreotide 20 Nivolumab 20 Specimen Handling 17 3-Iodobenzylguanidine 17 cabozantinib 16 Etoposide 16 Sunitinib 15 Capecitabine 14 surufatinib 13 pasireotide 13 lenvatinib 13 dabrafenib 13 Paclitaxel 13 Carboplatin 13 trametinib 12 Surgical Procedures, Operative 11 Doxorubicin 11 Bevacizumab 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Sorafenib 10 Ipilimumab 10 Injections 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03872401 2025-11-10

VESALIUS-CV

Amgen

Phase 3 Completed

12,301 enrolled

Coronary Disease, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡